Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone510-970-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$84.45 million
Profitability
Miscellaneous
Employees302
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions
What is Sangamo Therapeutics' stock symbol?
Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
How were Sangamo Therapeutics' earnings last quarter?
Sangamo Therapeutics Inc (NASDAQ:SGMO) announced its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The biopharmaceutical company earned $17.55 million during the quarter, compared to analyst estimates of $13.58 million. Sangamo Therapeutics had a negative return on equity of 27.32% and a negative net margin of 136.73%. The company's revenue for the quarter was down 18.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) earnings per share. View Sangamo Therapeutics' Earnings History.
When is Sangamo Therapeutics' next earnings date?
What price target have analysts set for SGMO?
4 brokerages have issued 12-month price targets for Sangamo Therapeutics' stock. Their forecasts range from $11.00 to $18.00. On average, they expect Sangamo Therapeutics' share price to reach $14.00 in the next year. This suggests a possible upside of 62.2% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.
What is the consensus analysts' recommendation for Sangamo Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sangamo Therapeutics.
Has Sangamo Therapeutics been receiving favorable news coverage?
Media headlines about SGMO stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sangamo Therapeutics earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Sangamo Therapeutics.
Who are some of Sangamo Therapeutics' key competitors?
Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Sangamo Therapeutics own?
Who are Sangamo Therapeutics' key executives?
Sangamo Therapeutics' management team includes the folowing people:
- Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
- Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
- Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
- Dr. Edward Rebar, Sr. VP & CTO
- Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations
Who are Sangamo Therapeutics' major shareholders?
Sangamo Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.64%), Bailard Inc. (0.22%), Vanguard Capital Wealth Advisors (0.03%) and Merriman Wealth Management LLC (0.02%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry and Steven J Mento. View Institutional Ownership Trends for Sangamo Therapeutics.
Which institutional investors are selling Sangamo Therapeutics stock?
SGMO stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Edward R Conner and Kathy Yi. View Insider Buying and Selling for Sangamo Therapeutics.
Which institutional investors are buying Sangamo Therapeutics stock?
How do I buy shares of Sangamo Therapeutics?
Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sangamo Therapeutics' stock price today?
One share of SGMO stock can currently be purchased for approximately $8.63.
How big of a company is Sangamo Therapeutics?
Sangamo Therapeutics has a market capitalization of $998.28 million and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.
What is Sangamo Therapeutics' official website?
How can I contact Sangamo Therapeutics?
Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]
MarketBeat Community Rating for Sangamo Therapeutics (NASDAQ SGMO)
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
